FDA-approved·Dual agonist (GLP-1 + GIP)
Tirzepatide
aka Mounjaro, Zepbound
Education only. Many compounds discussed are research chemicals not approved for human use in the US. This is not medical advice — consult a licensed physician.
What it is
FDA-approved dual GLP-1/GIP agonist marketed as Mounjaro (T2D) and Zepbound (obesity). Outperforms semaglutide on weight loss in head-to-head trials.
How it works
Activates both GLP-1 and GIP receptors. Suppresses appetite, slows gastric emptying, enhances glucose-dependent insulin secretion.
What the research says
SURMOUNT-1 trial showed up to 22.5% weight loss at 72 weeks at 15mg weekly.
Sources: NEJM SURMOUNT-1 · FDA label (Zepbound)
Common dosing ranges
- Range
- Start 2.5 mg/week, titrate to 15 mg/week max per FDA label
- Frequency
- Once weekly
- Duration
- Long-term per FDA label
Sources: FDA Zepbound label
Administration
SubQ
Half-life
~5 days
Side effects
Common
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
Serious / theoretical
- Pancreatitis
- Gallbladder disease
- Thyroid C-cell tumor warning
Sources: FDA label